SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
-4.76%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$1.85B
AUM Growth
+$1.85B
(-1.1%)
Cap. Flow
+$57.9M
Cap. Flow
% of AUM
3.13%
Top 10 Holdings %
Top 10 Hldgs %
47.07%
Holding
109
New
9
Increased
31
Reduced
10
Closed
22
Top Buys
| 1 |
Microsoft
MSFT
|
$68.9M |
| 2 |
Chipotle Mexican Grill
CMG
|
$37.4M |
| 3 |
Amazon
AMZN
|
$37.1M |
| 4 |
Advanced Micro Devices
AMD
|
$33.5M |
| 5 |
Royalty Pharma
RPRX
|
$28.5M |
Top Sells
| 1 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$67.2M |
| 2 |
XYZ
Block, Inc.
XYZ
|
$28.8M |
| 3 |
TSMC
TSM
|
$23.9M |
| 4 |
Accenture
ACN
|
$21.6M |
| 5 |
Canadian Pacific Kansas City
CP
|
$20.9M |
Sector Composition
| 1 | Healthcare | 62.92% |
| 2 | Consumer Discretionary | 12.25% |
| 3 | Technology | 11.13% |
| 4 | Communication Services | 4.55% |
| 5 | Industrials | 3.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arcutis Biotherapeutics
ARQT
$1.91B
| $6.03M | 0.33% |
1,135,227
+262,800
| +30% | +$1.4M |
|
52
Teva Pharmaceuticals
TEVA
$21.5B
| $5.07M | 0.27% |
+497,400
| New | +$5.07M |
|
53
AstraZeneca
AZN
$255B
| $4.77M | 0.26% |
70,490
+34,600
| +96% | +$2.34M |
|
54
BioNTech
BNTX
$24.1B
| $4.45M | 0.24% |
40,970
| – | – |
|
55
Danaher
DHR
$143B
| $4.08M | 0.22% |
18,530
| – | – |
|
56
Thermo Fisher Scientific
TMO
$183B
| $3.67M | 0.2% |
7,260
| – | – |
|
57
Kenvue
KVUE
$39.2B
| $3.45M | 0.19% |
+171,596
| New | +$3.45M |
|
58
PepGen
PEPG
$39M
| $2.47M | 0.13% |
486,611
| – | – |
|
59
Natera
NTRA
$23B
| $2.3M | 0.12% |
51,900
| – | – |
|
60
Cencora
COR
$57.2B
| $2.25M | 0.12% |
12,488
| – | – |
|
61
Nurix Therapeutics
NRIX
$723M
| $2.21M | 0.12% |
280,760
| – | – |
|
62
Incyte
INCY
$17B
| $2.17M | 0.12% |
37,600
| – | – |
|
|
AKLI
63
DELISTED
Akili, Inc. Common Stock
AKLI
| $2.11M | 0.11% |
3,841,718
| – | – |
|
64
Abbott
ABT
$230B
| $2M | 0.11% |
20,620
| – | – |
|
65
Spyre Therapeutics
SYRE
$1.02B
| $1.99M | 0.11% |
162,395
-1
| -0% | -$12 |
|
66
Protagonist Therapeutics
PTGX
$3.62B
| $1.81M | 0.1% |
108,308
+27,165
| +33% | +$453K |
|
67
Gilead Sciences
GILD
$140B
| $1.7M | 0.09% |
22,700
| – | – |
|
|
MOLN
68
Molecular Partners
MOLN
$139M
| $1.66M | 0.09% |
400,000
| – | – |
|
69
Galapagos
GLPG
$2.06B
| $1.63M | 0.09% |
47,200
| – | – |
|
70
IQVIA
IQV
$31.4B
| $1.41M | 0.08% |
7,175
| – | – |
|
71
argenx
ARGX
$44.2B
| $1.38M | 0.07% |
2,800
-590
| -17% | -$290K |
|
72
Medtronic
MDT
$118B
| $1.37M | 0.07% |
17,460
| – | – |
|
73
Elevance Health
ELV
$72.4B
| $1.31M | 0.07% |
3,010
| – | – |
|
74
CVS Health
CVS
$93B
| $1.2M | 0.06% |
17,170
| – | – |
|
75
Illumina
ILMN
$15.2B
| $1.2M | 0.06% |
8,974
| – | – |
|